BOSTON--(BUSINESS WIRE)--The DNA Repair Company (DNAR), an emerging company focused on personalized approaches to cancer treatment, announced today the licensing of the exclusive rights in North America for the use of a newly discovered diagnostic test that strongly predicts how women with breast cancer will respond to a common form of chemotherapy. The rights to the test were acquired from Helsinki University Central Hospital through Licentia Ltd.
